Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
Hugo Arias-PulidoAshley Marie Cimino-MathewsNabila ChaherClifford Ray QuallsNancy JosteCecile ColpaertJonathan Douglas MarottiMary Dickinson ChamberlinMaxwell Gabriel FoiseyEric Robert ProssnitzLeisha Ann EmensSteven FieringPublished in: Breast cancer research and treatment (2021)
CD20+PD-L1+TILs are an independent prognostic biomarker of improved outcomes in IBC, but not LABC. Selecting IBC patients by CD20 and PD-L1 status could stratify patients and potentially identify those in whom activating CD20 agents and anti-PD-1/PD-L1 therapy could be explored.